Biologics in Chronic Obstructive Pulmonary Disease: Current Status and Future Prospects.

However, a clear trend was observed: the RR progressively decreased as baseline BEC increased, suggesting a potential therapeutic benefit of mepolizumab for patients with higher levels of eosinophilic inflammation. 2) Confirmatory evidence from the MANTINEE trial The lessons from METREX and METREO informed the design of the MANTINEE trial, a large phase 3 study specifically aimed at confirming the therapeutic benefit of mepolizumab in an eosinophilic COPD population [ 22 ].

also in 11,406 other papers

While the NOTUS trial did not achieve statistical significance for mean SGRQ change, it indicated a numerical trend toward improvement.

also in 708 other papers